【摘要】 目的观察苯氧芳酸类降脂药物非诺贝特对肾移植患者血脂代谢和环孢素(CsA)浓度、尿酸水平的影响。方法56例高脂血症的肾移植患者服用微粒化的非诺贝特200mg/d,一个月后观察其血脂、尿酸水平和CsA浓度的改变。结果治疗一个月后所有患者甘油三酯(TG)和总胆固醇(T-CHOL)均降低,TG降低更为明显,同时高密度脂蛋白(HDL)水平升高,但低密度脂蛋白(LDL)降低没有统计学意义。CsA浓度用药前后无明显改变,尿酸水平降低。结论非诺贝特可显著改善肾移植患者的高TG血症,且对环孢素浓度影响不大。对高尿酸血症患者有降低尿酸作用。更多还原

【Abstract】 Objective To observe the influence of fenofibrate on hyperlipidemia and CsA concentration and uric acid in kidney transplantation.Methods Total 56 hyperlipidemic cases were treated 200mg/d fenofibrate for one month,then analyzed concentrations of serum lipids and CsA,etc.Results Treatment with fenofibrate for one month led to marked reduction in serum TG and T-CHOL,uric acid,the reduction of TG was more obvious.While change of LDL had no statistics’ means.At the same time serum HDL was increased.Concentration of CsA was unchanged.Conclusion Treatment with fenofibrate can decrease hyperlipidemia and uric acid in kidney transplantation recipients,and CsA concentration was unaffected.更多还原